We are live on
!
Find out more
ACM
ACT Capital Management Portfolio holdings
AUM
$153M
This Fund
S&P 500
This Quarter
Est. Return
+20.59%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$195M
AUM Growth
–
Cap. Flow
+$180M
Cap. Flow
% of AUM
92.65%
Top 10 Holdings %
Top 10 Hldgs %
56.76%
Holding
117
New
116
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
STAAR Surgical
STAA
|
+$30.5M |
| 2 |
Arrowhead Research
ARWR
|
+$15.5M |
| 3 |
Arcturus Therapeutics
ARCT
|
+$15.4M |
| 4 |
CLSD
Clearside Biomedical
CLSD
|
+$7.63M |
| 5 |
AWH
Aspira Women's Health Inc. Common Stock
AWH
|
+$6.48M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.63% |
| 2 | Technology | 6.05% |
| 3 | Communication Services | 5.12% |
| 4 | Financials | 3.37% |
| 5 | Consumer Staples | 1.53% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
STAAR Surgical
STAA
$1.14B
| $35.3M | 18.15% |
+231,600
| New | +$30.5M |
|
|
2
Arrowhead Research
ARWR
$12.2B
| $17.3M | 8.88% |
+208,600
| New | +$15.5M |
|
|
3
Arcturus Therapeutics
ARCT
$178M
| $15.4M | 7.92% |
+455,300
| New | +$15.4M |
|
|
CLSD
4
DELISTED
Clearside Biomedical
CLSD
| $12M | 6.16% |
+164,167
| New | +$7.63M |
|
5
FuboTV Inc
FUBO
$314M
| $8.61M | 4.42% |
+22,333
| New | +$6.38M |
|
|
AWH
6
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
| $6.36M | 3.27% |
+75,381
| New | +$6.48M |
|
|
TRIL
7
DELISTED
Trillium Therapeutics Inc.
TRIL
| $4.51M | 2.32% |
+465,000
| New | +$4.38M |
|
|
FLNA
8
Filana Therapeutics
FLNA
$46.4M
| $3.85M | 1.98% |
+45,000
| New | +$2.41M |
|
|
ICAD
9
DELISTED
iCAD Inc
ICAD
| $3.84M | 1.98% |
+222,000
| New | +$3.89M |
|
10
Unity
U
$15.5B
| $3.31M | 1.7% |
+30,100
| New | +$2.96M |
|
11
Upstart Holdings
UPST
$2.89B
| $3.1M | 1.59% |
+24,800
| New | +$3.05M |
|
12
Natera
NTRA
$39.3B
| $2.94M | 1.51% |
+25,900
| New | +$2.65M |
|
13
SkinHealth Systems
SKIN
$91.4M
| $2.9M | 1.49% |
+172,750
| New | +$2.36M |
|
14
Nektar Therapeutics
NKTR
$2.47B
| $2.77M | 1.42% |
+10,767
| New | +$2.98M |
|
15
F5
FFIV
$23.4B
| $2.71M | 1.39% |
+14,500
| New | +$2.79M |
|
16
Inhibikase Therapeutics
IKT
$377M
| $2.45M | 1.26% |
+145,833
| New | +$4.29M |
|
|
AFMD
17
DELISTED
Affimed
AFMD
| $2.44M | 1.26% |
+28,760
| New | +$2.62M |
|
18
Neurogene
NGNE
$718M
| $2.21M | 1.13% |
+11,950
| New | +$2.64M |
|
19
Novavax
NVAX
$1.27B
| $2.19M | 1.12% |
+10,300
| New | +$1.89M |
|
20
InMode
INMD
$874M
| $2.14M | 1.1% |
+45,200
| New | +$1.92M |
|
21
TG Therapeutics
TGTX
$7.64B
| $2.13M | 1.1% |
+55,000
| New | +$2.16M |
|
22
Aurinia Pharmaceuticals
AUPH
$1.95B
| $2.11M | 1.08% |
+162,500
| New | +$2.07M |
|
|
NUAN
23
DELISTED
Nuance Communications, Inc.
NUAN
| $2.04M | 1.05% |
+37,500
| New | +$1.98M |
|
|
MYOV
24
DELISTED
Myovant Sciences Ltd.
MYOV
| $1.99M | 1.02% |
+87,500
| New | +$1.84M |
|
|
IMDX
25
Insight Molecular Diagnostics
IMDX
$161M
| $1.9M | 0.97% |
+16,500
| New | +$1.61M |
|
Similar funds
BCI
APW
DAM
BVC
RHAM
RFN
SGM
HWM
ACT Capital Management's Q2 2021 Portfolio in Review
Q2 2021 is the first quarter with a 13F filing on record for ACT Capital Management, which disclosed 117 positions worth $195M. Its ten largest holdings account for 57% of the portfolio.
Its largest position is STAAR Surgical: 231,600 shares worth $35.3M.
By sector, the portfolio is most concentrated in Healthcare at 80% of assets, followed by Technology and Communication Services.
- ACT Capital Management's largest Q2 2021 buy was STAAR Surgical: 231,600 shares worth $35.3M.
- ACT Capital Management's ten largest holdings make up 57% of its $195M portfolio in Q2 2021.
- ACT Capital Management disclosed 117 positions in Q2 2021, its first 13F filing on record.
Based on ACT Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.